This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption
by Zacks Equity Research
CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.
VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal
by Zacks Equity Research
Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.
Selloff? What Selloff? Monday Market Rebound
by Mark Vickery
Palantir is way up after reporting Q2 results Monday afternoon, while HIMS and VRTX are way off highs.
Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of +6.60% and +2.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Stay Ahead of the Game With Vertex (VRTX) Q2 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Vertex (VRTX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $468.41 in the latest trading session, marking a +1.64% move from the prior day.
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
by Zacks Equity Research
Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $476.95, signifying a +1.45% move from its prior day's close.
Top Stock Reports for Wells Fargo, Abbott & American Express
by Mark Vickery
Wells Fargo gains post-Fed cap removal, Abbott rides strong devices pipeline, while AmEx sees growth but rising costs pinch margins.
Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?
by Zacks Equity Research
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $470.13, denoting a +2.54% move from the preceding trading day.
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $469.55 in the latest trading session, marking a +1.15% move from the prior day.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) reached $464.2 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
by Zacks Equity Research
NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
by Zacks Equity Research
VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) reached $452.16 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.